Emerging strategic

We are experiencing a renaissance in BioPharma. Robust specialty drug pipelines are promising paradigm-shifting innovation in notoriously challenging therapeutic areas like Oncology, Neurology, and Rare Disease. While promising, this progress comes at a cost – the influx of high price drug launches targeting a broader population is expected to threaten budget sustainability and lead to more aggressive payer action to erode price and restrict access.

To sustain portfolio value, drug manufacturers must be part of defining the solution, and “value-based” pricing is often identified as the ideal path forward. While this approach is promising, there are substantial challenges and considerations. 

On this Webcast, KPMG’s Pete Gilmore and Amy Hunckler will:

• Describe unique challenges that specialty drugs create to maintaining sustainability of healthcare budgets and optimizing manufacturer portfolio value
• Identify the opportunities and challenges that value-based pricing presents and the likely near-term stepping stones to more robust, long-term solutions
• Highlight how KPMG can support manufacturers in defining their value-based pricing strategy in terms of both internal capability development and external market shaping